OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HLYK.PK57

Healthlynked Corp

Healthcare Facilities & ServicesVerified

HealthLynked Corp operates with a negative equity position of -$5.76 million and a debt-to-equity ratio of -0.15, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is weak, with a current ratio of 0.22, suggesting limited ability to meet short-term obligations. The negative operating cash flow of -$1.71 million and free cash flow of -$3.18 million further highlight the company's cash flow challenges. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $3.28 million and an operating loss of $1.80 million, with a return on equity of 56.93% and a negative return on assets of -192.69%. These figures suggest poor capital efficiency and operational performance, particularly when compared to the preferred metrics in the healthcare technology industry. The company's revenue is distributed across three segments: Health Services, Digital Healthcare, and Medical Distribution. While the Medical Distribution segment (MedOffice Direct LLC) appears to be the primary revenue driver, the company's financial disclosures do not provide segment-specific revenue breakdowns. Geographically, the company is concentrated in the United States, with no disclosed international operations. The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The negative operating and free cash flows suggest a lack of sustainable growth and potential operational challenges. The absence of positive revenue history and the lack of forward-looking guidance make it difficult to assess the company's long-term growth potential. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential liquidity constraints. The low dilution risk is supported by the absence of recent equity issuance or dilutive events in the disclosed financial data. Recent events and filings do not provide additional insights into the company's operations or strategic direction. The lack of recent transcripts or filings beyond the financial snapshot limits the ability to assess management's strategic initiatives or operational updates.

30-day price · HLYK.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyHealthlynked Corp
TickerHLYK.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. HealthLynked Corp provides healthcare technology solutions through three segments: Health Services, Digital Healthcare, and Medical Distribution.

Classification. HealthLynked is classified in the Healthcare sector under Healthcare Services & Equipment, with a confidence level of 0.92.

HealthLynked Corp operates with a negative equity position of -$5.76 million and a debt-to-equity ratio of -0.15, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is weak, with a current ratio of 0.22, suggesting limited ability to meet short-term obligations. The negative operating cash flow of -$1.71 million and free cash flow of -$3.18 million further highlight the company's cash flow challenges. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $3.28 million and an operating loss of $1.80 million, with a return on equity of 56.93% and a negative return on assets of -192.69%. These figures suggest poor capital efficiency and operational performance, particularly when compared to the preferred metrics in the healthcare technology industry. The company's revenue is distributed across three segments: Health Services, Digital Healthcare, and Medical Distribution. While the Medical Distribution segment (MedOffice Direct LLC) appears to be the primary revenue driver, the company's financial disclosures do not provide segment-specific revenue breakdowns. Geographically, the company is concentrated in the United States, with no disclosed international operations. The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The negative operating and free cash flows suggest a lack of sustainable growth and potential operational challenges. The absence of positive revenue history and the lack of forward-looking guidance make it difficult to assess the company's long-term growth potential. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential liquidity constraints. The low dilution risk is supported by the absence of recent equity issuance or dilutive events in the disclosed financial data. Recent events and filings do not provide additional insights into the company's operations or strategic direction. The lack of recent transcripts or filings beyond the financial snapshot limits the ability to assess management's strategic initiatives or operational updates.
Key takeaways
  • The company's negative equity and weak liquidity position indicate significant financial distress.
  • Poor profitability metrics suggest operational inefficiencies and capital misallocation.
  • The lack of segment-specific revenue data and international exposure limits visibility into growth drivers.
  • The absence of positive cash flows and forward-looking guidance raises concerns about long-term sustainability.
  • --
  • ## RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$2.1M
Gross profit$1.0M
Operating income-$1.8M
Net income-$3.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.7M
CapEx
Free cash flow-$3.2M
Total assets$1.7M
Total liabilities$7.5M
Total equity-$5.8M
Cash & equivalents
Long-term debt$839.6k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$5.8M
Net cash-$839.6k
Current ratio0.2
Debt/Equity-0.1
ROA-1.9%
ROE56.9%
Cash conversion52.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricHLYK.PKActivity
Op margin-86.9%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin-158.8%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin50.4%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue4.2% medp25 3.8% · p75 4.2%
Debt / equity-15.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 02:44 UTC#e7408094
Source: analysis-pipeline (hybrid)Generated: 2026-05-05 02:46 UTCJob: 8c103a74